Abstract:Objective To study if the protective effect of dexmedetomidine on the pyohemia-associated delirium is through the cholinergic anti-inflammatory pathway.Methods Sixty male adult C57 mice were randomly divided into five groups (n=12 each): saline group (group C),dexmedetomidine (DEX) alone group (group DEX),endotoxemia (LPS) group (group LPS),dexmedetomidine protection group (group LPS+DEX) and alpha-bungarotoxin (α-BGT) group (group α-BGT).Each group were assigned to two subunits (n=6 each),mice in subunit one were sacrificed after examining the open field test,mice in subunit two were sacrificed after testing the novel object recognition.The level of inflammatory factors were measured by enzyme-linked immune sorbent assay (ELISA).The ultrastructure changes of the hippocampus in mice were observed by transmission electron microscopy.Results Compared with group C,there are no significant differences in group DEX.Dexmedetomidine significantly attenuated the delirious syndrome after LPS induced endotoxemia,however,the effect of dexmedetomidine disappeared in group α-BGT,and the syndrome of cognitive dysfunction in LPS group were more severe than that in group α-BGT.(1) The open field test show that there are no significant differences each group with that before model establishment;after the models were established 24 h,compared with group C,group LPS show that the abilities of cognition to new environment、learning and memory were decreasing,the tension is increasing.preemptive administration of dexmedetomidine significantly attenuated the delirious syndrome after LPS induced endotoxemia;however,preemptive administration of dexmedetomidine failed to control the delirious syndrome in group α-BGT.(2) The novel object recognition testshow that compared to group C,the ability of exploring the novel object is decreasing;preemptive administration of dexmedetomidine significantly improve the exploration ability,however,preemptive administration of dexmedetomidine failed to control the delirious syndrome in group α-BGT.(3) The results of ELISA show that: Compared with group C,the concentrations of tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β in serum and Hippocampus were all increased in LPS groups[Serum (ng/L) TNF-α: 794.80±93.99 vs.23.60±3.03,IL-1β: 148.49±24.80 vs.64.55±5.13,Hippocampus (pg/mg·prot) TNF-α: 176.14±11.25 vs.6.71±0.49,IL-1β: 50.61±5.86 vs.16.73±1.15,P=0.000],compared with group LPS,the concentrations were all significantly decreased in group LPS+DEX[Serum (ng/L) TNF-α: 184.44±26.58 vs.794.80±93.99,IL-1β: 77.43±10.75 vs.148.49±24.80,Hippocampus (pg/mg·prot) TNF-α: 64.83±13.09 vs.176.14±11.25,IL-1β: 17.97±2.26 vs.50.61±5.86,P=0.000].However,α-BGT can reverse the protective effect[Serum (ng/L): TNF-α: 812.31±86.25 vs.184.44±26.58,IL-1β: 156.42±17.94 vs.77.43±10.75,Hippocampus (pg/mg·prot) TNF-α: 181.94±8.69 vs.64.83±13.09,IL-1β: 52.10±5.59 vs.17.97±2.26,P=0.000].TEM shown that the histopathological damage of hippocampus tissue in group LPS and α-BGT were heavier,which in group LPS+DEX was reversed partially.Conclusion Central alpha-2 agonist dexmedetomidine attenuates sepsis-associated delirium syndrome likely through activating cholinergic anti-inflammatory pathway and inhibiting the inflammatory responses in serum and brain.

Dexmedetomidine protects against degeneration of dopaminergic neurons and improves motor activity in Parkinson's disease mice model

Dexmedetomidine attenuates motor deficits via restoring the function of neurons in the nigrostriatal circuit in Parkinson's disease model mice

Dexmedetomidine Suppresses Oxidative Stress and Inflammation of Nucleus Pulposus Cells by Activating the PI3K/Akt Signaling Pathway.

Both PI3K/Akt and ERK1/2 Pathways Participate in the Protection by Dexmedetomidine Against Transient Focal Cerebral Ischemia/reperfusion Injury in Rats

Dexmedetomidine, an alpha-2 adrenoceptors agonist, provides a neuroprotective effect for dopaminergic neurons in the substantia nigra and attenuates glucose imbalance in the 6-hydroxydopamine animal model of Parkinson's disease

Neuroprotective Effect of Dextromethorphan in the MPTP Parkinson's Disease Model: Role of NADPH Oxidase

Neuroprotective Effects Against Cerebral Ischemic Injury Exerted by Dexmedetomidine via the HDAC5/NPAS4/MDM2/PSD-95 Axis

Dexmedetomidine attenuates pyohemia-associated delirium in mice through the cholinergic anti-inflammatory pathway

Dexmedetomidine Exerts an Anti-Inflammatory Effect Via Α2 Adrenoceptors to Alleviate Cognitive Dysfunction in 5xfad Mice.

Dexmedetomidine Promotes Spinal Cord Repair and Nerve Regeneration Through Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling and Oxidative Stress

Novel D3 Dopamine Receptor-Preferring Agonist D-264: Evidence of Neuroprotective Property in Parkinson'S Disease Animal Models Induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Lactacystin

Dexmedetomidine Improves Anxiety-like Behaviors in Sleep-Deprived Mice by Inhibiting the p38/MSK1/NFκB Pathway and Reducing Inflammation and Oxidative Stress

[Dihydromyricetin Alleviates Pyroptosis and Necroptosis in Mice with MPTP-induced Chronic Parkinson's Disease by Inducing Autophagy].

Neuroprotective Effects of Dexamethasone in a Neuromelanin-Driven Parkinson's Disease Model

Dexmedetomidine Exerts an Anti-inflammatory Effect via α2 Adrenoceptors to Prevent Lipopolysaccharide-induced Cognitive Decline in Mice.

Dexmedetomidine exerts cerebral protective effects against cerebral ischemic injury by promoting the polarization of M2 microglia via the Nrf2/HO-1/NLRP3 pathway

Dextromethorphan Protects Dopaminergic Neurons Against Inflammation-Mediated Degeneration Through Inhibition of Microglial Activation

Daidzein exerts neuroprotective activity against MPTP‐induced Parkinson's disease in experimental mice and lipopolysaccharide‐induced BV2 microglial cells

Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease

DEXMEDETOMIDINE AMELIORATES ACUTE BRAIN INJURY INDUCED BY MYOCARDIAL ISCHEMIA-REPERFUSION VIA UPREGULATING THE HIF-1 PATHWAY

DEXMEDETOMIDINE PREVENTS PDIA3 DECREASE BY ACTIVATING Α2-Adrenergic RECEPTOR TO ALLEVIATE INTESTINAL I/R IN MICE.